Just received an update from MBLTY.
"Until the acquisition of Angioblast is ratified by Mesoblast shareholders, the ownership of Angioblast remains at 38.4%. We shall update the website after the Extraordinary General Meeting."
"Until the acquisition of Angioblast is ratified by Mesoblast shareholders, the ownership of Angioblast remains at 38.4%. We shall update the website after the Extraordinary General Meeting."
Recent MESO News
- Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It • PR Newswire (US) • 05/22/2026 02:31:00 PM
- Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It • PR Newswire (Canada) • 05/22/2026 02:31:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/30/2026 11:54:03 AM
- Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million • GlobeNewswire Inc. • 04/30/2026 12:55:01 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/29/2026 10:02:23 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 01:58:24 AM
- Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain • GlobeNewswire Inc. • 04/29/2026 12:53:16 AM
- Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products • GlobeNewswire Inc. • 04/15/2026 12:10:56 AM
- Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION • GlobeNewswire Inc. • 04/10/2026 08:09:52 PM
- Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation • GlobeNewswire Inc. • 04/08/2026 01:07:53 PM
- Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 04/08/2026 03:35:17 AM
- Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter • GlobeNewswire Inc. • 04/07/2026 01:03:58 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 12:00:19 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/23/2026 11:52:13 AM
- The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed • GlobeNewswire Inc. • 03/18/2026 03:30:00 PM
- A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. • PR Newswire (Canada) • 03/18/2026 02:00:00 PM
- A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. • PR Newswire (US) • 03/18/2026 02:00:00 PM
- Mesoblast to Host R&D Day on April 8, 2026 • GlobeNewswire Inc. • 03/17/2026 11:19:57 PM
- Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast • GlobeNewswire Inc. • 03/11/2026 11:21:39 PM
- Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them • PR Newswire (Canada) • 03/03/2026 03:02:00 PM

